Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes

Table 1 Mortality in men with type 2 diabetes stratified by treatment with statins, testosterone status/treatment, phosphodiesterase 5-inhibitors and combinations of treatments n (%)

	Total group	Alive	Deceased	P value
Patient n	857	754	103
Mean age at death or last visit/SD (yr)	67.4/11.6	66.2/11.3	76.2/10.2	< 0.00011
Patient numbers (%) stratified by treatment
Statin/untreated	195 (22.8)	162 (21.5)	33 (32.0)	0.0172
Statin/treated	662 (77.3)	592 (78.5)	70 (68.0)
Normal T/untreated	320 (37.3)	284 (37.7)	36 (35.0)	< 0.0012
Low T/untreated	362 (42.2)	301 (39.9)	61 (59.2)
Low T/treated	175 (20.4)	169 (22.4)	6 (5.8)
PDE5I/untreated	682 (79.6)	582 (77.2)	100 (97.1)	< 0.0012
PDE5I/treated	175 (20.4)	172 (22.8)	3 (2.9)
Not on any of the above therapeutic agents	125 (14.6)	92 (12.2)	33 (32.0)	0.0022
On all 3 therapeutic agents	45 (5.3)	43 (5.7)	2 (1.9)

¹Unpaired t test;

²χ² analysis.